|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Lycera Corporation
| | | Phone: | (646) 440 9464 | Year Established: | 2006 | Main Contact: | Bruce A. Goldsmith, Ph.D., CBO | | Other Contacts: | Peter L. Toogood, Ph.D., Senior VP, Chemistry and Chemical Biology JoAnn Scatina, Ph.D., Senior VP, Preclinical Development Laura L. Carter, Ph.D., Senior VP, Biology Alex G. Howarth, CFO Paul Sekhri, President & CEO
| | Company Description | Lycera Corp. is focused on the discovery and development of selective, small-molecule immune-modulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Lycera is developing drug candidates for novel therapeutic targets that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Lycera is focused on the emerging areas of cellular bioenergetics and immune-metabolism to selectively target and silence pathologically activated cells. Lycera's leadership team and advisors represent the core thought leaders in immunology, inflammation, medicinal chemistry and relevant biology and are responsible for key advances and discoveries in these fields. | |
|
|
|
|
|